Get the Stockscreener App
43.89
5.13%
2.14
After Hours:
43.89
Structure Therapeutics Inc Adr stock is traded at $43.89, with a volume of 692.15K.
It is up +5.13% in the last 24 hours and up +15.11% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$41.75
Open:
$42.39
24h Volume:
692.15K
Relative Volume:
0.90
Market Cap:
$2.46B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-20.43
EPS:
-2.1478
Net Cash Flow:
$-105.32M
1W Performance:
+3.64%
1M Performance:
+15.11%
6M Performance:
+2.40%
1Y Performance:
-12.95%
1-Day Range:
$42.00
$44.72
1-Week Range:
$40.62
$45.22
52-Week Range:
$26.61
$75.02
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Ratios Uncovered: Breaking Down Structure Therapeutics Inc ADR (GPCR)’s Trailing Twelve Months Metrics - The Dwinnex
Structure Therapeutics Inc ADR (GPCR) expanding its growth trajectory ahead - SETE News
Perceptive Advisors LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: small-cap biotech's stock potential in obesity market - Investing.com
18,803 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Scientech Research LLC - MarketBeat
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? - Insider Monkey
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? - Yahoo Finance
Blue Owl Capital Holdings LP Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Closing Figures Unveiled: Structure Therapeutics Inc ADR (GPCR) Drop -4.70, Closes at 41.95 - The Dwinnex
183,785 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Ensign Peak Advisors Inc - MarketBeat
Does Structure Therapeutics Inc ADR (GPCR) offer a good opportunity for investors? - SETE News
Cantor Fitzgerald Weighs in on Structure Therapeutics Inc.'s FY2024 Earnings (NASDAQ:GPCR) - MarketBeat
1,000 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Sandia Investment Management LP - Defense World
First Light Asset Management LLC Buys 441,534 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc ADR (GPCR)’s stock chart: A technical perspective - US Post News
First Light Asset Management LLC Buys 441,534 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 7.1% - Defense World
Structure Therapeutics (NASDAQ:GPCR) Shares Up 7.1% - MarketBeat
HighVista Strategies LLC Has $1.38 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc ADR: Weathering Stock Market Storms with 2.40B Market Cap - The InvestChronicle
HighVista Strategies LLC Buys 19,338 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
HighVista Strategies LLC Reduces Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Structure Therapeutics (NASDAQ:GPCR) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated at Morgan Stanley - MarketBeat
American Century Companies Inc. Has $17.08 Million Stake in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up to $38.75 - MarketBeat
Structure Therapeutics Inc ADR (NASDAQ: GPCR): Getting A Free Pass? - Stocks Register
34,337 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Seven Eight Capital LP - MarketBeat
What is the investor’s view on Structure Therapeutics Inc ADR (GPCR)? - US Post News
High-Flying Novo Nordisk Dips on Disappointing Data for Weight-Loss Pill - The Wall Street Journal
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5% - Defense World
Analyzing Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) and Structure Therapeutics (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest - MarketBeat
Structure Therapeutics Announces Key Executive Leadership Changes - TipRanks
Structure Therapeutics reshapes leadership team ahead of trials - Investing.com
Structure Therapeutics reshuffles top brass ahead of clinical trials - Investing.com
Structure Therapeutics reshapes leadership team ahead of trials - Investing.com India
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer - StockTitan
Structure Therapeutics (NASDAQ:GPCR) Given Overweight Rating at Cantor Fitzgerald - Defense World
Structure Therapeutics' (GPCR) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading Down 5% - MarketBeat
Deeper Dive: Understanding Structure Therapeutics Inc ADR (GPCR) Through its Various Ratios - The Dwinnex
Get in on Structure Therapeutics Inc ADR’s (GPCR) buy-in window today! - SETE News
Natixis Advisors LLC Has $746,000 Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Federated Hermes Inc. Has $94.53 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise - Yahoo Finance
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy - Yahoo Finance
GPCR’s Debt-to-Equity Ratio at 0.01: What It Means for Structure Therapeutics Inc ADR’s Future - The InvestChronicle
Structure Therapeutics (NASDAQ:GPCR) Shares Up 14.6% - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):